Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
The research of Jack R. Andrews, M.D., a fellowship urologic oncologist, focuses on the treatment of prostate cancer. He completed his residency at Mayo Clinic and his fellowship at MD Anderson Cancer Center.
His research focus includes clinical trials, implementation of Prostate Specific Membrane Antigen (PSMA) PET/CT, Lutetium PSMA theranostics, metastasis directed therapies in oligometastatic prostate cancer, expanding active surveillance and biomarker development. PSMA therapy uses a radioactive material to kill prostate cancer cells. Theranostics combines diagnosis and treatment to kill cancer. Dr. Andrews spearheaded the Nautilus Trial, which represents the first Lutetium PSMA randomized controlled trial in the pre-surgical space.
Dr. Andrew's research improves outcomes to people through biomarker development and implementation of PSMA PET directed care. He is a leader in using Lutetium PSMA theranostics. He wrote the world's first Lutetium PSMA theranostic randomized controlled trial and hopes to bring Lutetium PSMA theranostics to early disease treatment. Dr. Andrews serves as Mayo Clinic site investigator for the Phase 3 BEYER ARASTEP trial.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Ver mis estudios.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.